210
Participants
Start Date
December 20, 2024
Primary Completion Date
March 1, 2028
Study Completion Date
March 1, 2028
Proactive TDM-based dosing of secukinumab
"Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
Proactive TDM-based dosing of ixekizumab
"Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
Proactive TDM-based dosing of guselkumab
"Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week"
NOT_YET_RECRUITING
AZ Alma, Eeklo
RECRUITING
AZ Sint-Jan, Bruges
RECRUITING
UCL Saint-Luc, Brussels
NOT_YET_RECRUITING
ULB Erasme, Brussels
NOT_YET_RECRUITING
UZ Brussel, Brussels
NOT_YET_RECRUITING
Grand Hôpital de Charleroi, Charleroi
NOT_YET_RECRUITING
Dermatologiepraktijk huidziekten Geel, Geel
RECRUITING
AZ Maria Middelares, Ghent
RECRUITING
UZ Gent, Ghent
RECRUITING
Clinique André Renard, Herstal
RECRUITING
Dermatologie Handelskaai, Kortrijk
NOT_YET_RECRUITING
UZ Leuven, Leuven
RECRUITING
Dermatologie Maldegem, Maldegem
Belgium Health Care Knowledge Centre
OTHER_GOV
University Hospital, Ghent
OTHER